APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Coccidioidomycosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Coccidioidomycosis Drug Market Outlook and Growth Opportunities 2026

Report ID 173979140419 December 2025191 pages

Choose your research edition.

Industry ResearchCoccidioidomycosis Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Coccidioidomycosis Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Coccidioidomycosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Coccidioidomycosis Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Coccidioidomycosis Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Coccidioidomycosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Coccidioidomycosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Coccidioidomycosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Coccidioidomycosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Coccidioidomycosis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Coccidioidomycosis Drug market include Yi Kang Pharm, Teva Pharmaceuticals, ShiJiaZhuang No.4 Pharmaceutical, Qilu Pharmaceutical Group, Minsheng Pharmaceutical, Mylan, Lunan Pharmaceutical, Kelun and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Coccidioidomycosis Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Coccidioidomycosis Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Coccidioidomycosis Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Coccidioidomycosis Drug market.

Coccidioidomycosis Drug Segment by Company

Yi Kang Pharm

Teva Pharmaceuticals

ShiJiaZhuang No.4 Pharmaceutical

Qilu Pharmaceutical Group

Minsheng Pharmaceutical

Mylan

Lunan Pharmaceutical

Kelun

Pfizer

Bayer

Baxter

Sanofi-Aventis

Hexal

Apotex

Coccidioidomycosis Drug Segment by Type

Voriconazole

Fluconazole

Amphotericin B

Posaconazole

Others

Coccidioidomycosis Drug Segment by Application

Hospital

Retail

Others

Coccidioidomycosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Coccidioidomycosis Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Coccidioidomycosis Drug key companies, revenue, market share, and recent developments.

3. To split the Coccidioidomycosis Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Coccidioidomycosis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Coccidioidomycosis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Coccidioidomycosis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coccidioidomycosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Coccidioidomycosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coccidioidomycosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Coccidioidomycosis Drug industry.

Chapter 3: Detailed analysis of Coccidioidomycosis Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Coccidioidomycosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Coccidioidomycosis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Coccidioidomycosis Drug Industry Trends Table 2. Coccidioidomycosis Drug Industry Drivers Table 3. Coccidioidomycosis Drug Industry Opportunities and Challenges Table 4. Coccidioidomycosis Drug Industry Restraints Table 5. Global Coccidioidomycosis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Coccidioidomycosis Drug Revenue Share by Company (2021-2026) Table 7. Global Coccidioidomycosis Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Coccidioidomycosis Drug Key Company Manufacturing Base & Headquarters Table 9. Global Coccidioidomycosis Drug Company, Product Type & Application Table 10. Global Coccidioidomycosis Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Coccidioidomycosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Voriconazole Table 15. Significant Companies of Fluconazole Table 16. Significant Companies of Amphotericin B Table 17. Significant Companies of Posaconazole Table 18. Significant Companies of Others Table 19. Global Coccidioidomycosis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Coccidioidomycosis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Coccidioidomycosis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Coccidioidomycosis Drug Sales Value Share by Type (2021-2026) Table 23. Global Coccidioidomycosis Drug Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Retail Table 26. Significant Companies of Others Table 27. Global Coccidioidomycosis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Coccidioidomycosis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Coccidioidomycosis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Coccidioidomycosis Drug Sales Value Share by Application (2021-2026) Table 31. Global Coccidioidomycosis Drug Sales Value Share by Application (2027-2032) Table 32. Global Coccidioidomycosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Coccidioidomycosis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Coccidioidomycosis Drug Sales Value Share by Region (2021-2026) Table 35. Global Coccidioidomycosis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Coccidioidomycosis Drug Sales Value Share by Region (2027-2032) Table 37. Global Coccidioidomycosis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Coccidioidomycosis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Coccidioidomycosis Drug Sales Value Market Share by Country (2021-2026) Table 40. Global Coccidioidomycosis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Coccidioidomycosis Drug Sales Value Market Share by Country (2027-2032) Table 42. Yi Kang Pharm Company Information Table 43. Yi Kang Pharm Business Overview Table 44. Yi Kang Pharm Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Yi Kang Pharm Coccidioidomycosis Drug Product Portfolio Table 46. Yi Kang Pharm Recent Development Table 47. Teva Pharmaceuticals Company Information Table 48. Teva Pharmaceuticals Business Overview Table 49. Teva Pharmaceuticals Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Teva Pharmaceuticals Coccidioidomycosis Drug Product Portfolio Table 51. Teva Pharmaceuticals Recent Development Table 52. ShiJiaZhuang No.4 Pharmaceutical Company Information Table 53. ShiJiaZhuang No.4 Pharmaceutical Business Overview Table 54. ShiJiaZhuang No.4 Pharmaceutical Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. ShiJiaZhuang No.4 Pharmaceutical Coccidioidomycosis Drug Product Portfolio Table 56. ShiJiaZhuang No.4 Pharmaceutical Recent Development Table 57. Qilu Pharmaceutical Group Company Information Table 58. Qilu Pharmaceutical Group Business Overview Table 59. Qilu Pharmaceutical Group Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Qilu Pharmaceutical Group Coccidioidomycosis Drug Product Portfolio Table 61. Qilu Pharmaceutical Group Recent Development Table 62. Minsheng Pharmaceutical Company Information Table 63. Minsheng Pharmaceutical Business Overview Table 64. Minsheng Pharmaceutical Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Minsheng Pharmaceutical Coccidioidomycosis Drug Product Portfolio Table 66. Minsheng Pharmaceutical Recent Development Table 67. Mylan Company Information Table 68. Mylan Business Overview Table 69. Mylan Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Mylan Coccidioidomycosis Drug Product Portfolio Table 71. Mylan Recent Development Table 72. Lunan Pharmaceutical Company Information Table 73. Lunan Pharmaceutical Business Overview Table 74. Lunan Pharmaceutical Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Lunan Pharmaceutical Coccidioidomycosis Drug Product Portfolio Table 76. Lunan Pharmaceutical Recent Development Table 77. Kelun Company Information Table 78. Kelun Business Overview Table 79. Kelun Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Kelun Coccidioidomycosis Drug Product Portfolio Table 81. Kelun Recent Development Table 82. Pfizer Company Information Table 83. Pfizer Business Overview Table 84. Pfizer Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Pfizer Coccidioidomycosis Drug Product Portfolio Table 86. Pfizer Recent Development Table 87. Bayer Company Information Table 88. Bayer Business Overview Table 89. Bayer Coccidioidomycosis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Bayer Coccidioidomycosis Drug Product Portfolio Table 91. Bayer Recent Development Table 92. Baxter Company Information Table 93. Baxter Business Overview Table 94. Baxter Coccidioidomycosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Baxter Coccidioidomycosis Drug Product Portfolio Table 96. Baxter Recent Development Table 97. Sanofi-Aventis Company Information Table 98. Sanofi-Aventis Business Overview Table 99. Sanofi-Aventis Coccidioidomycosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Sanofi-Aventis Coccidioidomycosis Drug Product Portfolio Table 101. Sanofi-Aventis Recent Development Table 102. Hexal Company Information Table 103. Hexal Business Overview Table 104. Hexal Coccidioidomycosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Hexal Coccidioidomycosis Drug Product Portfolio Table 106. Hexal Recent Development Table 107. Apotex Company Information Table 108. Apotex Business Overview Table 109. Apotex Coccidioidomycosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Apotex Coccidioidomycosis Drug Product Portfolio Table 111. Apotex Recent Development Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Coccidioidomycosis Drug Product Image Figure 2. Global Coccidioidomycosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Coccidioidomycosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Coccidioidomycosis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Voriconazole Image Figure 8. Fluconazole Image Figure 9. Amphotericin B Image Figure 10. Posaconazole Image Figure 11. Others Image Figure 12. Global Coccidioidomycosis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Coccidioidomycosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Coccidioidomycosis Drug Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Retail Image Figure 17. Others Image Figure 18. Global Coccidioidomycosis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Coccidioidomycosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Coccidioidomycosis Drug Sales Value Share by Application (2021-2032) Figure 21. Global Coccidioidomycosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Coccidioidomycosis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Coccidioidomycosis Drug Sales Value (2021-2032) & (US$ Million) Figure 24. North America Coccidioidomycosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Coccidioidomycosis Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Coccidioidomycosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Coccidioidomycosis Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Coccidioidomycosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Coccidioidomycosis Drug Sales Value (2021-2032) & (US$ Million) Figure 30. South America Coccidioidomycosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Coccidioidomycosis Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Coccidioidomycosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Voriconazole
  • Fluconazole
  • Amphotericin B
  • Posaconazole
  • Others
Applications
  • Hospital
  • Retail
  • Others
Companies covered
  • Yi Kang Pharm
  • Teva Pharmaceuticals
  • ShiJiaZhuang No.4 Pharmaceutical
  • Qilu Pharmaceutical Group
  • Minsheng Pharmaceutical
  • Mylan
  • Lunan Pharmaceutical
  • Kelun
  • Pfizer
  • Bayer
  • Baxter
  • Sanofi-Aventis
  • Hexal
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Coccidioidomycosis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Coccidioidomycosis Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Coccidioidomycosis Drug Market Dynamics
  1. 2.1 Coccidioidomycosis Drug Industry Trends
  2. 2.2 Coccidioidomycosis Drug Industry Drivers
  3. 2.3 Coccidioidomycosis Drug Industry Opportunities and Challenges
  4. 2.4 Coccidioidomycosis Drug Industry Restraints
3 Coccidioidomycosis Drug Market by Company
  1. 3.1 Global Coccidioidomycosis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Coccidioidomycosis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Coccidioidomycosis Drug Company Ranking (2024-2026)
  4. 3.4 Global Coccidioidomycosis Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Coccidioidomycosis Drug Company Product Type and Application
  6. 3.6 Global Coccidioidomycosis Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Coccidioidomycosis Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Coccidioidomycosis Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Coccidioidomycosis Drug Market by Type
  1. 4.1 Coccidioidomycosis Drug Type Introduction
  2. 4.1.1 Voriconazole
  3. 4.1.2 Fluconazole
  4. 4.1.3 Amphotericin B
  5. 4.1.4 Posaconazole
  6. 4.1.5 Others
  7. 4.2 Global Coccidioidomycosis Drug Sales Value by Type
  8. 4.2.1 Global Coccidioidomycosis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Coccidioidomycosis Drug Sales Value by Type (2021-2032)
  10. 4.2.3 Global Coccidioidomycosis Drug Sales Value Share by Type (2021-2032)
5 Coccidioidomycosis Drug Market by Application
  1. 5.1 Coccidioidomycosis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail
  4. 5.1.3 Others
  5. 5.2 Global Coccidioidomycosis Drug Sales Value by Application
  6. 5.2.1 Global Coccidioidomycosis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Coccidioidomycosis Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Coccidioidomycosis Drug Sales Value Share by Application (2021-2032)
6 Coccidioidomycosis Drug Regional Value Analysis
  1. 6.1 Global Coccidioidomycosis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Coccidioidomycosis Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Coccidioidomycosis Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Coccidioidomycosis Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Coccidioidomycosis Drug Sales Value (2021-2032)
  7. 6.3.2 North America Coccidioidomycosis Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Coccidioidomycosis Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Coccidioidomycosis Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Coccidioidomycosis Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Coccidioidomycosis Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Coccidioidomycosis Drug Sales Value (2021-2032)
  16. 6.6.2 South America Coccidioidomycosis Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Coccidioidomycosis Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Coccidioidomycosis Drug Sales Value Share by Country, 2025 VS 2032
7 Coccidioidomycosis Drug Country-level Value Analysis
  1. 7.1 Global Coccidioidomycosis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Coccidioidomycosis Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Coccidioidomycosis Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Coccidioidomycosis Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Coccidioidomycosis Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Coccidioidomycosis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Coccidioidomycosis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yi Kang Pharm
  2. 8.1.1 Yi Kang Pharm Company Information
  3. 8.1.2 Yi Kang Pharm Business Overview
  4. 8.1.3 Yi Kang Pharm Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yi Kang Pharm Coccidioidomycosis Drug Product Portfolio
  6. 8.1.5 Yi Kang Pharm Recent Developments
  7. 8.2 Teva Pharmaceuticals
  8. 8.2.1 Teva Pharmaceuticals Company Information
  9. 8.2.2 Teva Pharmaceuticals Business Overview
  10. 8.2.3 Teva Pharmaceuticals Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceuticals Coccidioidomycosis Drug Product Portfolio
  12. 8.2.5 Teva Pharmaceuticals Recent Developments
  13. 8.3 ShiJiaZhuang No.4 Pharmaceutical
  14. 8.3.1 ShiJiaZhuang No.4 Pharmaceutical Company Information
  15. 8.3.2 ShiJiaZhuang No.4 Pharmaceutical Business Overview
  16. 8.3.3 ShiJiaZhuang No.4 Pharmaceutical Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ShiJiaZhuang No.4 Pharmaceutical Coccidioidomycosis Drug Product Portfolio
  18. 8.3.5 ShiJiaZhuang No.4 Pharmaceutical Recent Developments
  19. 8.4 Qilu Pharmaceutical Group
  20. 8.4.1 Qilu Pharmaceutical Group Company Information
  21. 8.4.2 Qilu Pharmaceutical Group Business Overview
  22. 8.4.3 Qilu Pharmaceutical Group Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Qilu Pharmaceutical Group Coccidioidomycosis Drug Product Portfolio
  24. 8.4.5 Qilu Pharmaceutical Group Recent Developments
  25. 8.5 Minsheng Pharmaceutical
  26. 8.5.1 Minsheng Pharmaceutical Company Information
  27. 8.5.2 Minsheng Pharmaceutical Business Overview
  28. 8.5.3 Minsheng Pharmaceutical Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Minsheng Pharmaceutical Coccidioidomycosis Drug Product Portfolio
  30. 8.5.5 Minsheng Pharmaceutical Recent Developments
  31. 8.6 Mylan
  32. 8.6.1 Mylan Company Information
  33. 8.6.2 Mylan Business Overview
  34. 8.6.3 Mylan Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mylan Coccidioidomycosis Drug Product Portfolio
  36. 8.6.5 Mylan Recent Developments
  37. 8.7 Lunan Pharmaceutical
  38. 8.7.1 Lunan Pharmaceutical Company Information
  39. 8.7.2 Lunan Pharmaceutical Business Overview
  40. 8.7.3 Lunan Pharmaceutical Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lunan Pharmaceutical Coccidioidomycosis Drug Product Portfolio
  42. 8.7.5 Lunan Pharmaceutical Recent Developments
  43. 8.8 Kelun
  44. 8.8.1 Kelun Company Information
  45. 8.8.2 Kelun Business Overview
  46. 8.8.3 Kelun Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kelun Coccidioidomycosis Drug Product Portfolio
  48. 8.8.5 Kelun Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Coccidioidomycosis Drug Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Coccidioidomycosis Drug Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Baxter
  62. 8.11.1 Baxter Company Information
  63. 8.11.2 Baxter Business Overview
  64. 8.11.3 Baxter Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Baxter Coccidioidomycosis Drug Product Portfolio
  66. 8.11.5 Baxter Recent Developments
  67. 8.12 Sanofi-Aventis
  68. 8.12.1 Sanofi-Aventis Company Information
  69. 8.12.2 Sanofi-Aventis Business Overview
  70. 8.12.3 Sanofi-Aventis Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi-Aventis Coccidioidomycosis Drug Product Portfolio
  72. 8.12.5 Sanofi-Aventis Recent Developments
  73. 8.13 Hexal
  74. 8.13.1 Hexal Company Information
  75. 8.13.2 Hexal Business Overview
  76. 8.13.3 Hexal Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Hexal Coccidioidomycosis Drug Product Portfolio
  78. 8.13.5 Hexal Recent Developments
  79. 8.14 Apotex
  80. 8.14.1 Apotex Company Information
  81. 8.14.2 Apotex Business Overview
  82. 8.14.3 Apotex Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Apotex Coccidioidomycosis Drug Product Portfolio
  84. 8.14.5 Apotex Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst